DAJY(SZ:002030)2022-12-08 01:28Group 1: Company Overview - The main business of the company includes reagent products, instrument products, and providing testing services [3] - The company has advantages over competitors by offering both its own products and testing services, while others may only provide one or the other [3] Group 2: Impact of Medical Reform - Prior to medical reform, diagnostic fees accounted for less than 10% of hospital revenue; this has increased to an average of 15%, with some hospitals reaching 25%-30% [3] - The role of diagnostic departments in hospitals has shifted from auxiliary to mainstream, indicating a growing importance of diagnostics in treatment [3] Group 3: Product Registration and Revenue Distribution - The company has obtained national medical device registration for its non-invasive prenatal screening product, with no other products currently approved [4] - Revenue from reagent products is primarily derived from PCR diagnostic reagents, which account for approximately 70%-80% of reagent income [4] Group 4: Genetic Testing Applications - Susceptibility gene testing can be applied to the detection of tumors and genetic diseases, serving as a health indicator to predict the likelihood of future diseases [4]